Clinical trials in Chaidari – page 67

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Non-small cell lung cancer

Not recruiting

Study to Compare Fianlimab and Cemiplimab Combination with Cemiplimab Alone for Adults with Advanced Non-Small Cell Lung Cancer

Registered drug

Study to Compare Fianlimab and Cemiplimab Combination with Cemiplimab Alone for Adults with Advanced Non-Small Cell Lung Cancer

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug

Greece

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on Vudalimab or Pembrolizumab with Chemotherapy for Advanced Non-small Cell Lung Cancer Patients

Registered drugNo placebo

Study on Vudalimab or Pembrolizumab with Chemotherapy for Advanced Non-small Cell Lung Cancer Patients

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Xencor Inc.

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Alectinib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Idiopathic pulmonary fibrosis

Not recruiting

Study on Fipaxalparant for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Study on Fipaxalparant for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Greece

Participants:18–64 years · 65+ years
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Malignant peritoneal neoplasm+2

Not recruiting

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Selpercatinib
Sponsor:Eli Lilly & Co.

Contact Research Centre

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of Crinecerfont for Children with Classic Congenital Adrenal Hyperplasia

Investigational

Study on the Safety and Effectiveness of Crinecerfont for Children with Classic Congenital Adrenal Hyperplasia

Investigational

Greece

Participants:0–17 years
Substances:Crinecerfont
Sponsor:Neurocrine Biosciences Inc.

Contact Research Centre

Thrombotic microangiopathy

Not recruiting

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Chronic myeloid leukaemia+2

Not recruiting

Study on the Dose and Safety of Asciminib in Children with Chronic Myeloid Leukemia

Registered drugNo placebo

Study on the Dose and Safety of Asciminib in Children with Chronic Myeloid Leukemia

Registered drugNo placebo

Greece

Participants:0–17 years
Substances:Asciminib
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries